Present studies on RBM5 anti-tumor mechanisms are mostly focused on its apoptosis induction role, such as: RBM5 overexpression enhanced TRAIL-, TNF-alpha-, Fas-, and P53-mediated apoptosis[20, 27, 28], increased the expression of Stat5b, BMP5[29], Bax[17], and proapoptotic Casp-2 L[30], and decreased the expression of Amplified In Breast Cancer 1 (AIB1), proto-oncogene Pim-1, caspase antagonist BIRC3 (cIAP-2, MIHC), and cyclin-dependent kinase 2 (CDK2)[29]. Here, CDK2 is linked to neoplasm.